Cardiovascular implications of HIV-associated dyslipidemic lipodystrophy

被引：14
作者：
Sekhar R.V. [1 ]
Jahoor F. [1 ]
Pownall H.J. [1 ]
Ballantyne C.M. [1 ]
Balasubramanyam A. [1 ]
机构：
[1] Division of Endocrinology, Baylor College of Medicine, Houston, TX 77030, One Baylor Plaza
来源：
Current Atherosclerosis Reports | 2004年 / 6卷 / 3期
基金：
美国国家卫生研究院;
关键词：
Insulin Resistance; Cholesteryl Ester Transfer Protein; Lipodystrophy; Postprandial Lipemia; Intramyocellular Lipid;
D O I：
10.1007/s11883-004-0029-2
中图分类号：
学科分类号：
摘要：
The emergence of a new metabolic syndrome in patients with HIV infection, termed "HIV-associated dyslipidemic lipodystrophy" (HADL), is characterized by central fat redistribution, severe dyslipidemia, and insulin resistance and predisposes to an increased risk of cardiovascular disease. The factors promoting the development of cardiovascular disease in this condition are not well understood and may involve contributions from antiretroviral drugs and components of the HIV virus, as well as inflammatory cytokines, leading to accelerated lipolysis, dyslipidemia, lipotoxic insulin resistance, and vascular inflammation. In this article, we review HADL in terms of metabolic, molecular, and cytokine derangements leading to cardiovascular disease. Copyright © 2004 by Current Science Inc.
引用
收藏
页码：173 / 179
页数：6
相关论文
共 50 条
  • [1] HIV-associated lipodystrophy syndrome
    Mauss, S
    AIDS, 2000, 14 : S197 - S207
  • [2] HIV-associated lipodystrophy syndrome
    Milinkovic, Ana
    COLLEGIUM ANTROPOLOGICUM, 2006, 30 : 59 - 62
  • [3] HIV-ASSOCIATED LIPODYSTROPHY AND EXERCISE
    Mutimura, E.
    Stewart, A.
    Crowther, N. J.
    SOUTH AFRICAN JOURNAL OF PHYSIOTHERAPY, 2006, 62 (02) : 2 - 4
  • [4] Clinical management of HIV-associated lipodystrophy
    Pirmohamed, Munir
    CURRENT OPINION IN LIPIDOLOGY, 2009, 20 (04) : 309 - 314
  • [5] The Role of Protease Inhibitors in the Pathogenesis of HIV-Associated Lipodystrophy: Cellular Mechanisms and Clinical Implications
    Flint, Oliver P.
    Noor, Mustafa A.
    Hruz, Paul W.
    Hylemon, Phil B.
    Yarasheski, Kevin
    Kotler, Donald P.
    Parker, Rex A.
    Bellamine, Aouatef
    TOXICOLOGIC PATHOLOGY, 2009, 37 (01) : 65 - 77
  • [6] Leptin in congenital and HIV-associated lipodystrophy
    Tsoukas, Michael A.
    Farr, Olivia M.
    Mantzoros, Christos S.
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2015, 64 (01): : 47 - 59
  • [7] Pharmacologic therapy for HIV-associated lipodystrophy
    Benavides, S
    Nahata, MC
    ANNALS OF PHARMACOTHERAPY, 2004, 38 (03) : 448 - 457
  • [8] HIV-associated lipodystrophy: Pathogenesis, prognosis, treatment, and controversies
    Koutkia, P
    Grinspoon, S
    ANNUAL REVIEW OF MEDICINE, 2004, 55 : 303 - 317
  • [9] The natural history of HIV-associated lipodystrophy in the changing scenario of HIV infection
    Guaraldi, G.
    Stentarelli, C.
    Zona, S.
    Santoro, A.
    Beghetto, B.
    Carli, F.
    Orlando, G.
    Franceschetto, A.
    Casolo, A.
    Mussini, C.
    HIV MEDICINE, 2014, 15 (10) : 587 - 594
  • [10] Buffalo hump seen in HIV-associated lipodystrophy is associated with hyperinsulinemia but not dyslipidemia
    Mallon, PWG
    Wand, H
    Law, M
    Miller, J
    Cooper, DA
    Carr, A
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2005, 38 (02) : 156 - 162
12345